Showing 201-210 of 9754 results for "".
Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuDermWireTV: AbbVie's Science of Skin Panel, Monkeypox Warning, Recommendations on Skin Cancer Detection Devices, UV Filters and Aquatic Life
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-abbvies-science-of-skin-panel-monkeypox-warning-recommendations-on-skin-cancer-detection-devices-uv-filters-and-aquatic-life/20131/“The Science of Skin: United Beyond the Surface” program sponsored by AbbVie brings together leading dermatologists and patients or caregivers of patients with dermatologic disease to explore the burden of skin diseases on diverse populations and the need for optimized treatment approaches. Seemal DAlmirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.Vitiligo Uncovered: Exploring the Latest Advances in Treatment and Care
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/vitiligo-uncovered-exploring-latest-advances-treatment-and-care/29519/In this on-demand webinar, Dr. Domingues and Dr. Silverberg provide a comprehensive overview of vitiligo. This session covers the various types of vitiligo, essential patient evaluation techniques, and understanding disease progression. Learn about treatment strategies from both private practice andASDS: Dr. Munavalli on Combining Lasers and Topicals for Skin Cancer
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-munavalli-combining-lasers-and-topicals-skin-cancer/29151/Girish Munavalli, MD, MHS, FAAD, discusses his lecture on lasers in combination with topical medications in the treatment of skin cancer at the 2024 American Society for Dermatologic Surgery Annual Meeting.Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuDermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addresFrax Pro and CoolSculpting Elite Launch, Antibiotic Resistance in Rosacea, Thriving in Aesthetics Rolls Out
https://practicaldermatology.com/series/dermwire-tv/frax-pro-and-coolsculpting-elite-launch-antibiotic-resistance-in-rosacea-thriving-in-aesthetics-rolls-out/19896/The majority of rosacea patients have never heard of antibiotic resistance, a new survey reported by the National Rosacea Society finds. Candela’s Frax Pro system is now available, featuring Frax 1550 and the novel Frax 1940 applicators. Allergan Aesthetics, an AbbVie company, is launching CoolSculp